Zimmer Biomet surges on earnings beat, $1.5B buyback authorization
Medical device maker raises 2026 EPS guidance despite sales model transition
Zimmer Biomet Holdings reported stronger-than-expected fourth-quarter earnings and authorized a $1.5 billion stock repurchase program, sending shares higher as investors embraced the medical device maker's confidence in its long-term growth trajectory despite near-term strategic transitions.
The Indiana-based company posted adjusted diluted earnings per share of $2.42 for the quarter ended December 31, 2025, exceeding analyst expectations. Net sales reached $2.244 billion, representing 10.9% growth on a reported basis and solidifying what executives described as a "strong close" to the year.
For the full year 2025, Zimmer Biomet generated $8.232 billion in net sales, a 7.2% increase from the prior year, while adjusted diluted EPS grew 2.5% to $8.20. The company's board of directors approved the $1.5 billion repurchase authorization on February 9, with the program carrying no expiration date and designed to return capital to shareholders while minimizing dilution from employee stock issuances.
Looking ahead, Zimmer Biomet provided 2026 adjusted diluted EPS guidance of $8.30 to $8.45, representing an increase from the $8.20 achieved in 2025. The company anticipates reported revenue growth between 2.5% and 4.5% for the full year, reflecting what management described as the impact of a strategic transition to a predominantly direct and specialized sales organization in the United States.
Ivan Tornos, chairman, president and chief executive officer, acknowledged that "this bold action tempers our 2026 sales guidance" but emphasized the company's confidence that the sales model overhaul "will drive durable long-term growth and solidify our position as the undisputed market leader." The direct sales transition marks a significant shift from the company's previous distribution model, allowing for greater control over customer relationships and potentially improving margins over time.
Zimmer Biomet's shares have faced pressure in recent months, trading below their 52-week high of $113.56 amid broader market volatility and concerns about the orthopedic device market's growth prospects. The stock currently trades at a forward price-to-earnings ratio of approximately 10.6 times, well below many large-cap medical technology peers, with an analyst consensus target price of $102.74 suggesting significant upside potential.
The company's market capitalization stands at approximately $17.8 billion, with institutional investors holding virtually all outstanding shares. Zimmer Biomet maintains a dividend yield of 1.08%, having paid its most recent quarterly dividend in January.
The earnings beat and capital return announcement come at a crucial time for Zimmer Biomet, which has been working to reignite growth through product innovation and market expansion initiatives. The company's portfolio spans orthopedic reconstructive products, surgical solutions, and dental technologies, positioning it to benefit from aging demographics and increased demand for joint replacement procedures globally.
Analysts will be watching closely in the coming quarters for evidence that the direct sales model transition is gaining traction and whether the company can maintain momentum in its core markets while integrating new product launches. The substantial buyback authorization suggests management believes current share prices undervalue the company's long-term earnings power as it executes on its strategic transformation.